Introduction
============

Vesicoureteral reflux (VUR) is one of the most common anomalies of the urinary tract in children and is associated with reflux nephropathy ([@b1-etm-0-0-6793]). It is particularly important to perform screening for VUR in children with hydronephrosis at the fetal stage or repetitive febrile infection of the urinary tract to avoid the development of reflex nephropathy ([@b2-etm-0-0-6793]). However, the correlation between VUR and chronic nephropathy remains controversial ([@b3-etm-0-0-6793]). It is often recommended that high-risk children should be excluded from VUR, particular for those with hydronephrosis, scarred kidney and complicated infection of the urinary tract ([@b4-etm-0-0-6793]). At present, three methods are typically used to diagnose VUR: Retrograde voiding cystourethrogram with X-ray (VCUG), radionuclide cystography (RNC) and contrast-enhanced voiding urosonography (CeVUS) ([@b5-etm-0-0-6793]). The first two methods involve irradiation and intermittent imaging, and thus have limited sensitivity ([@b6-etm-0-0-6793]). Following the development of second-generation contrast agents and high definition ultrasound equipment, CeVUS has become the primary screening method for children with suspected VUR in Europe, with a diagnostic accuracy of 78--96% ([@b7-etm-0-0-6793],[@b8-etm-0-0-6793]). CeVUS has 80--100% sensitivity, 77--97% specificity and an increased positive diagnosis rate compared with VCUG and RNC ([@b9-etm-0-0-6793]--[@b11-etm-0-0-6793]). In addition, ultrasound has the advantage of being radiation-free, which allows for longer scanning times, making VUR screening in children more practical and allowing for repeated follow up scans. However, CeVUS is not popular in China and there is no standard operating practice for the procedure ([@b7-etm-0-0-6793]). The aim of the present study was to analyze the sensitivity and safety of CeVUS as a diagnostic tool for VUR in children and to develop a standard procedure for its clinical application in China.

Materials and methods
=====================

### General information

A total of 90 Chinese children with repetitive urinary tract infection, complicated urinary tract infection, hydrophrosis at the fetal stage or abnormal urine at birth were enrolled in the present study. All participants were considered to be at a high risk for developing VUR. Patients were admitted to the Pediatric Nephrology Department of Tongji Hospital (Wuhan, China) between August 2016 and October 2017. Of these patients, 47 were female and 43 were male. A total of 2 newborn cases were included and the mean age was 36.6 months (range, 0.5--155 months). Study protocols were approved by the Institutional Review Board of Tongji Hospital (Huazhong University of Science and Technology, Wuhan, China; study ID, TJ-C 20160311) and informed consent was signed by the guardians of all participants.

### CeVUS examination

All children were subjected to middle-segment urine culture, and the bacterial number was calculated. The bladder volume of the children was calculated using the following equation: Volume (ml)=(age in years + 2) ×30 ([@b7-etm-0-0-6793]). Prior to examination, a urinary catheter was placed in the bladder and connected to a stopcock. After the bladder was emptied of urine, the catheter was clipped and the stopcock was closed. Patients were placed in the spine position without a sedative. The bilateral kidneys were recorded using a color LOGIQ E9 Ultrasound Doppler equipped with built-in harmonic imaging software and a 4 MHz convex array harmonic imaging probe (GE Healthcare, Chicago, IL, USA) to assess the morphology, renal parenchyma echo, the collecting system and the bilateral ureters. The images were captured with a mechanical index of 0.08. The SonoVue^®^ contrast agent (Bracco, Milan, Italy), the major component of which is sulphur hexafluoride powder-coated with liposomes. Prior to examination, the contrast agent (59 mg) was mixed with 5 ml aseptic saline and agitated evenly to form a solution of microbubbles (diameter, \<10 µm). Warm saline at 1/3 of the bladder volume and 1 ml microbubble solution were perfused into the bladder via the catheter. Warm saline (2/3 of the bladder volume) was continuously dripped into the bladder using infusion apparatus at a height of 1 m. The catheter was opened and children were asked to urinate, with pressure as required on the bladder to push the urine out. After the contrast agent was injected, contrast ultrasound images were captured to continuously scan the unilateral renal pelvis, ureter and bladder. The steps of contrast ultrasound imaging were repeated for the contralateral renal pelvis and the ureter. The perineum was also scanned to examine the urethra. Preventive antibiotics (cefaclor 20 mg/kg) were used prior to, during and after the examination.

### VCUG examination

Cyclic VCUG was conducted using a digital fluoroscopic system (Siemens AG, Munich, Germany) according to a previous study ([@b12-etm-0-0-6793]). Briefly, intermittent pulsed fluoroscopy was performed in all the patients. The bladder was filled with radiographic contrast agent at body temperature using a trough urinary catheter by drip infusion. Two films were captured during the filling phase, one or two films were captured during voiding and one film was captured post voiding. VUR was diagnosed when radiographic contrast medium was observed in the ureter or pelvicalyceal system and was graded according to the International Reflux System of grading ([@b7-etm-0-0-6793]).

### VUR grading standard

VUR was graded according to the following criteria: Grade I, contrast agent present only in the ureter; Grade II, contrast agent present in the ureter and renal pelvis without dilation of the renal pelvis; Grade III, contrast agent present in the ureter and renal pelvis with mild dilation of the renal pelvis; Grade IV, contrast agent present in the ureter and renal pelvis with dilations of the pelvis and calices, and clear carcunculae paillaris; Grade V, contrast agent present in the ureter and pelvis, with clear dilation of the pelvis and calices, disappearance of carcunculae paillaris and tortuous expansion of the ureter.

### Statistical analysis

Statistical analysis was performed using SPSS 11.0 (SPSS, Inc., Chicago, IL, USA) software. Data were presented as mean ± SD. The Chi-square test was used to determine statistical differences between the groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical data

A total of 90 children were enrolled in the present study, including 1 with left repetitive kidney and 3 with unilateral kidney ([Table I](#tI-etm-0-0-6793){ref-type="table"}; [Figs. 1](#f1-etm-0-0-6793){ref-type="fig"} and [2](#f2-etm-0-0-6793){ref-type="fig"}), resulting in a total of 178 Pyelo-Ureteral Units (PUUs). The colonies of bacterial over a specific area reached \>10^5^/ml in 25 cases. Kidney function was normal in all children (estimated glomerular filtration rate, \>110 ml/1.73 m^2^/min). Urine examination revealed that 88 children were considered to have a urinary tract infection, which presented ≥2 times. The remaining 2 newborns exhibited white blood cells in their urine. Detailed patient information is presented in [Table I](#tI-etm-0-0-6793){ref-type="table"}.

### VUR detection with CeVUS

The CeVUS examination revealed that 44/90 children (48.89%) had VUR, including 23 cases of unilateral VUR and 21 cases of bilateral VUR ([Table II](#tII-etm-0-0-6793){ref-type="table"}). A total of 27 females and 17 males (39.53%) were diagnosed with VUR (57.45%) l. Of the 178 PUUs, 65 were diagnosed with VUR (36.52%), including 32/88 left PUUs (36.36%) and 33/90 right PUUs (36.67%). The grades of diagnosed VURs are listed in [Table III](#tIII-etm-0-0-6793){ref-type="table"} and representative images of patients with CeVUS are presented in [Figs. 3](#f3-etm-0-0-6793){ref-type="fig"}--[7](#f7-etm-0-0-6793){ref-type="fig"}.

### Urine culture and VUR diagnosis using CeVUS

In the 25 children with a positive urine culture prior to CeVUS examination, 20 (80%) were diagnosed with VUR, including 19 at Grade III or higher (95%) and 11 at Grade V or higher (55%). There were 14 cases of VUR at Grade V, 11 (78.57%) of which were positive for urine culture. In the 5 cases with positive urine culture but negative VUR as assessed by CeVUS examination, 2 (49 and 56) were neurogenic bladder, 1 (35) had a larger bladder volume and 2 (22 and 34) were negative, as confirmed by repeated VCUG.

A total of 2 patients (number 4 and 23) were diagnosed with Grade III VUR by CeVUS, although the VCUG examination was negative. Patient 15 was diagnosed with Grade II/III VUR by VCUG, but CeVUS gave a diagnosis of Grade III/IV.

### SonoVue concentration for VUR screening using CeVUS

The mean bladder volume was 151.5 ml and the mean SonoVue concentration was 0.88% (0.22--1.63%; [Table I](#tI-etm-0-0-6793){ref-type="table"}).

### Statistics results

The results indicated that there was no statistical difference in detection rate of VUR between male and female patients ([Table IV](#tIV-etm-0-0-6793){ref-type="table"}; P\>0.05) or between left and right ureters (P\>0.05; [Table V](#tV-etm-0-0-6793){ref-type="table"}).

Discussion
==========

It has been proposed that chronic kidney disease in children with VUR is derived from primary scar formation or the development of kidney abnormalities (renal dysplasia and hypoplasia), while VUR is only accompanied by developmental abnormality ([@b13-etm-0-0-6793]--[@b15-etm-0-0-6793]). VCUG is considered to be the gold standard for VUR diagnosis; however, its application is limited in children for a number of reasons, including clinical sensitivity, detection rate and radiation exposure ([@b16-etm-0-0-6793]). In 1997, the American Urology Association proposed a VCUG diagnostic strategy with minimal side effects ([@b7-etm-0-0-6793]). Following this, a number of studies have indicated that CeVUS has a higher sensitivity compared with VCUG. The application of harmonic ultrasound further enhanced the specificity of CeVUS in the diagnosis of VUR ([@b11-etm-0-0-6793]), making it a reliable diagnostic method in Europe ([@b17-etm-0-0-6793]). In the present study, 44/90 children (48.79%) and 65/178 PUUs (36.52%) were diagnosed as VUR positive using CeVUS, which is consistent with a previous study ([@b18-etm-0-0-6793]) and suggests that \>50% of high-risk children were VUR negative. VCUG results for 2 children indicated that they were VUR negative, whereas CeVUS later revealed that they were positive for VUR. Although a comparative study was not performed, this suggests that CeVUS has an increased sensitivity compared with VCUG.

Following the development and clinical application of second-generation contrast agents and high definition ultrasound apparatus, CeVUS has been widely used to diagnose VUR in children ([@b19-etm-0-0-6793],[@b20-etm-0-0-6793]). By combining with VCUG, CeVUS has partially replaced VCUG. Large comparative studies have indicated that the sensitivity of CeVUS is significantly increased compared with VCUG, reaching 80--100% ([@b9-etm-0-0-6793],[@b11-etm-0-0-6793],[@b21-etm-0-0-6793],[@b22-etm-0-0-6793]). In the present study, children who were demonstrated to be negative for VUR by CeVUS examination were also negative for VUR in the VCUG examination, while 2 children who were determined to be negative for VUR by VCUG were later diagnosed with unilateral Grade III VUR using CeVUS scanning. These results are consistent with a previous study ([@b23-etm-0-0-6793]) and suggest that VCUG is not sensitive enough to diagnose Grade III VUR due to its intermittent scanning ([@b19-etm-0-0-6793]).

Of the 25 children with a positive urine culture, 20 were diagnosed as being VUR positive, including 19 children (95%) with Grade III or higher VUR and 11 children (55%) with Grade V VUR. The patients with Grade V VUR and positive urine culture accounted for 78.57% of the 14 children with Grade V VUR, which suggests that there is an association between positive urine culture and VUR. Therefore, the authors suggest that preliminary VUR screening with CeVUS should be performed on all children with \>10^5^ bacterial number in urine cultures.

Large-scale pediatric studies have not directly associated adverse responses in SonoVue with CeVUS ([@b24-etm-0-0-6793],[@b25-etm-0-0-6793]). In 2008, the World Federation for Ultrasound in Medicine and Biology and the European Ultrasound Association published guidelines for its clinical application ([@b25-etm-0-0-6793]), while Safe Examination Guidelines for Children were launched in 2033 ([@b26-etm-0-0-6793]). These guidelines are which are widely used to diagnose pediatric VUR in European and American countries. In the present study, 90 children did not exhibit any adverse responses to CeVUS examination, which is indicative of the high safety of CeVUS. VUR was clearly observed (cases 3, 7 and 89) when the contrast agent was used at 0.22--0.3%, which was markedly lower than the first generation contrast agent used by Darge *et al* ([@b27-etm-0-0-6793]). The authors the use of 1 ml SonoVue for screening VUR with CeVUS in Chinese children, which is consistent with a previous report ([@b11-etm-0-0-6793]) and meets the recommended standard ([@b25-etm-0-0-6793]).

In summary, the present study supports the safety and efficacy of CeVUS as an innoxious and sensitive tool for screening VUR in high-risk children. It has been recommended as the first-choice for screening and follow-up of VUR diagnosis and urethral diseases in children and should include screening of the kidney and bladder via the perineum to identify urethral diseases.

![Two-dimensional ultrasound image of repetitive kidney, which has left side complication with hydronephrosis. The upper collecting system is separated with reciprocal connection of the echo-free region (arrow head), while the lower collecting system is not separated (arrow). L, left; R, right.](etm-16-06-4546-g00){#f1-etm-0-0-6793}

![(A) Two-dimensional ultrasound image and (B) contrast-enhanced voiding urosonography images of the kidney in which the left side exhibits complication with hydronephrosis. A contrast agent was present in the upper collecting system (arrow head) and an expanded tortuous ureter was observed (arrow). The contrast agent did not appear in the lower collecting system (star).](etm-16-06-4546-g01){#f2-etm-0-0-6793}

![(A) Two-dimensional ultrasound image and (B) contrast-enhanced voiding urosonography image of a Grade I vesicoureteral reflux on the left side. The contrast agent appeared intermittently in the ureter (arrow) but not in the pelvis.](etm-16-06-4546-g02){#f3-etm-0-0-6793}

![(A) Two-dimensional ultrasound image and (B) contrast-enhanced voiding urosonography image of a Grade II VUR on the right side. Contrast agent appeared in the pelvis and ureter without expansion of the pelvis (arrow).](etm-16-06-4546-g03){#f4-etm-0-0-6793}

![(A) Two-dimensional ultrasound image and (B) contrast-enhanced voiding urosonography image of a Grade III vesicoureteral reflux on the left side. Contrast agent appeared in the pelvis and ureter with mild expansion of the pelvis (arrow).](etm-16-06-4546-g04){#f5-etm-0-0-6793}

![(A) Two-dimensional ultrasound image and (B) contrast-enhanced voiding urosonography image of a Grade IV vesicoureteral reflux on the left side. Contrast agent appeared in the pelvis and ureter with expansion of the pelvis and the appearance of carunclulae papillaris (arrow).](etm-16-06-4546-g05){#f6-etm-0-0-6793}

![(A) Two-dimensional ultrasound image and (B) contrast-enhanced voiding urosonography image of a Grade V vesicoureteral reflux on the left side. The contrast agent appeared in the pelvis and ureter with clear expansion of the pelvis and calices, and disappearance of carunclulae papillaris (arrow).](etm-16-06-4546-g06){#f7-etm-0-0-6793}

###### 

Clinical data of the children enrolled in the study.

                                                                              VUR degrade           
  -------------------------------------------------- --- ----- ------- ------ ------------- ------- ------------
  1                                                  F   8     80.0    1.25   N               III   *K. pneu*
  2                                                  F   7     77.5    1.29   II            N       N
  3                                                  F   114   345.0   0.29   I             II      *E. coli*
  4                                                  F   41    162.5   0.62   III           N       N
  5                                                  F   49    182.5   0.55   N             N       N
  6^[a](#tfn1-etm-0-0-6793){ref-type="table-fn"}^    F   0.5   61.25   1.63   V/N\*         V       *E. faeci*
  7                                                  F   134   395.0   0.25   IV            I       *E. coli*
  8                                                  F   4     70.0    1.43   N             V       *E. faeci*
  9                                                  F   94    295.0   0.34   N             N       N
  10                                                 F   1     62.5    1.60   N             N       N
  11                                                 F   40    160.0   0.63   II            IV      *K. pneu*
  12                                                 F   10    85.0    1.18   N             N       N
  13                                                 F   76    250.0   0.40   N             I       N
  14                                                 F   3     67.5    1.48   IV            III     N
  15                                                 F   27    127.5   0.78   III           IV      N
  16                                                 F   7     77.5    1.29   N             N       N
  17                                                 F   90    285.0   0.35   N             N       N
  18                                                 F   7     77.5    1.29   IV            IV      *E. coli*
  19                                                 F   32    140.0   0.71   III           N       N
  20                                                 F   93    292.5   0.34   N             N       N
  21                                                 F   45    172.5   0.58   N             N       N
  22                                                 F   15    97.5    1.03   N             N       *E. coli*
  23                                                 F   29    132.5   0.75   N             III     N
  24                                                 F   104   320.0   0.31   N             N       N
  25                                                 F   9     82.5    1.21   N             N       N
  26                                                 F   6     75.0    1.33   N             III     N
  27                                                 F   54    195.0   0.51   II            III     *E. coli*
  28                                                 F   36    150.0   0.67   IV            N       N
  29                                                 F   3     67.5    1.48   IV            V       *P. aeru*
  30                                                 F   44    170.0   0.59   Abs           N       N
  31                                                 F   17    102.5   0.98   Abs           III     N
  32                                                 F   72    240.0   0.42   N             N       N
  33                                                 F   3     67.5    1.48   IV            IV      *E. coli*
  34                                                 F   96    300.0   0.33   N             N       *E. coli*
  35                                                 F   93    292.5   0.34   N             N       *E. coli*
  36                                                 F   113   342.5   0.29   N             N       N
  37                                                 F   40    160.0   0.63   N             IV      N
  38                                                 F   3     67.5    1.48   N             N       N
  39                                                 F   4     70.0    1.43   IV            V       *E. coli*
  40                                                 F   60    210.0   0.48   II            II      N
  41                                                 F   57    202.5   0.49   II            N       N
  42                                                 F   37    152.5   0.66   IV            N       N
  43                                                 F   9     82.5    1.21   III           N       N
  44                                                 F   11    87.5    1.14   N             N       N
  45                                                 F   21    112.5   0.89   N             N       N
  46                                                 F   53    192.5   0.52   III           IV      N
  47                                                 F   6     75.0    1.33   N             N       N
  48                                                 M   31    137.5   0.73   V             N       *P. aeru*
  49                                                 M   21    112.5   0.89   N             N       *P. aeru*
  50                                                 M   38    155.0   0.65   N             N       N
  51                                                 M   33    142.5   0.70   N             N       N
  52                                                 M   45    172.5   0.58   N             N       N
  53                                                 M   5     72.5    1.38   N             N       N
  54                                                 M   11    87.5    1.14   N             N       N
  55                                                 M   6     75.0    1.33   IV            V       *E. faeci*
  56^[b](#tfn2-etm-0-0-6793){ref-type="table-fn"}^   M   7     77.5    1.29   N             N       *E. cloa*
  57                                                 M   28    130.0   0.77   N             N       N
  58                                                 M   14    95.0    1.05   N             V       N
  59                                                 M   23    117.5   0.85   N             N       N
  60                                                 M   24    120.0   0.83   III           V       *E. coli*
  61                                                 M   6     75.0    1.33   N             N       N
  62                                                 M   49    182.5   0.55   Abs           IV      N
  63                                                 M   108   330.0   0.30   N             N       N
  64                                                 M   30    135.0   0.74   N             N       N
  65                                                 M   33    142.5   0.70   N             N       N
  66                                                 M   110   335.0   0.30   N             N       N
  67                                                 M   7     77.5    1.29   N             N       N
  68                                                 M   81    262.5   0.38   N             V       *Stap*.
  69                                                 M   18    105.0   0.95   III           V       *M. subsp*
  70                                                 M   15    97.5    1.03   IV            N       N
  71                                                 M   16    100.0   1.00   N             N       N
  72                                                 M   6     75.0    1.33   N             N       N
  73                                                 M   4     70.0    1.43   N             N       N
  74                                                 M   15    97.5    1.03   IV            N       *S. malt*
  75                                                 M   6     75.0    1.33   V             V       *E. coli*
  76                                                 M   2     65.0    1.54   V             V       *E. faeca*
  77                                                 M   28    130.0   0.77   II            N       N
  78                                                 M   81    262.5   0.38   N             V       N
  79                                                 M   22    115.0   0.87   IV            V       N
  80                                                 M   37    152.5   0.66   N             N       N
  81                                                 M   6     75.0    1.33   IV            IV      *E. faeci*
  82                                                 M   16    100.0   1.00   N             N       N
  83                                                 M   80    260.0   0.38   N             N       N
  84                                                 M   37    152.5   0.66   II            III     N
  85                                                 M   8     80.0    1.25   N             N       N
  86                                                 M   9     82.5    1.21   N             N       N
  87                                                 M   20    110.0   0.91   N             N       N
  88                                                 M   8     80.0    1.25   N             N       N
  89                                                 M   155   447.5   0.22   N             IV      N
  90                                                 M   119   357.5   0.28   N             N       N

Left repetitive kidney with hyronephrosis

complication of the neurogenic bladder; Abs, kidney absence; N, negative; VUR, vesicoureteral reflux; L, left kidney; R, right kidney; F, female; M, male; *E. coli, Escherichia coli; K. pneu, Klebsiella pneumoniae; E. faeca, Enterococcus faecalis; E. faeci, Enterococcus faecium; P. aeru, Pseudomonas aeruginosa; S. malt, Stenotrophomonas maltophilia; Stap., Staphylococcus; M. subsp, Morganella morganii subspecies; E. cloa, Enterobacter cloacae*.

###### 

VUR results with ultrasound contrast-enhanced voiding urosonography in children.

                VUR diagnosis               
  -------- ---- --------------- ----- ----- ------------
  Male     43     4               5     8   17 (39.53)
  Female   47     7               7   13    27 (57.45)
  Total    90   11              12    21    44 (48.89)

VUR, vesicoureteral reflux.

###### 

Grading of VUR with ultrasound contrast-enhanced voiding urosonography.

                  VUR                         
  -------- ------ ----- --- ----- ----- ----- ------------
  Male       85   0     2     3     8   12    25 (29.41)
  Female     93   3     7   11    14      5   40 (43.01)
  Total    178    3     9   14    22    17    65 (36.52)

PPU, Pyelo-Ureteral Units; VUR, vesicoureteral reflux.

###### 

Comparison of ureter number and case number with VUR between different genders of children.

  Gender   VUR+      VUR-       Total
  -------- --------- ---------- ----------
  Male     25 (17)   60 (26)    85 (43)
  Female   40 (27)   53 (20)    93 (47)
  Total    65 (44)   113 (46)   178 (90)

The contents of the brackets represent the number of cases. VUR, vesicoureteral reflux.

###### 

Comparison of VUR number between left and right ureters of children.

  Orientation   VUR+   VUR-   Total
  ------------- ------ ------ -------
  Left          32       56     88
  Right         33       57     90
  Total         65     113    178

VUR, vesicoureteral reflux.
